Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

Sperinde, Jeff; Jin, Xueguang; Banerjee, Jayee; Penuel, Elicia; Saha, Anasuya; Diedrich, Gundo; Huang, Weidong; Leitzel, Kim; Weidler, Jodi; M. Ali, Suhail; Fuchs, Eva‐Maria; F. Singer, Christian; J. Köstler, Wolfgang; Bates, Michael; Parry, Gordon; Winslow, John; Lipton, Allan

doi:10.1158/1078-0432.ccr-10-0410

Public

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

Published in Clinical Cancer Research • Jul 27, 2010

Authors:

Jeff Sperinde

Xueguang Jin

Jayee Banerjee

Abstract

PURPOSE: p95HER2 is an NH(2)-terminally truncated form of HER2 that lacks the trastuzumab binding site and is therefore thought to confer resistance to trastuzumab treatment. In this report, we introduce a new antibody that has enabled the first direct quantitative measurement of p95HER2 in formalin...

Subject

Trastuzumab

Metastatic breast cancer

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!